On Friday, Shares of Halliburton Company (NYSE:HAL), SUBTRACT -0.11% and closed at $46.97 in the last trading session. The last trading range of the stock ranges between $46.84 and $47.83. Halliburton Company (HAL) and U.S. Silica Holdings, Inc. (SLCA) announced today the companies have moved a record breaking unit train carrying nearly 19,000 tons of U.S. Silica White® frac sand from Ottawa, Ill., to Elmendorf, Texas. The train, the largest frac sand unit of its kind shipped to date in North America, arrived today via the BNSF railroad. Unit trains reduce transit time from mine to transload facility.
“Utilizing sand unit trains enables Halliburton to respond to customers’ needs on a shorter timeline and deliver cost efficient sand on location to drive the lowest cost per BOE,” said Richard Gonzalez, vice president of Production Enhancement for Halliburton. “Our extensive infrastructure along with a great working relationship with U.S. Silica highlights our strength in collaborating and engineering solutions to maximize asset value for customers.”
“Unit train delivery, leveraging our combined logistical assets, is the most efficient and cost effective way to deliver high volumes of sand in the time constraints required,” said Don Weinheimer, senior vice president and president of Oil and Gas for U.S. Silica. “Unit train capability is increasingly critical to our customers success as sand demand per well continues to ramp up.”
Gilead Sciences, Inc. (NASDAQ:GILD), DROPPED -0.42% and closed at $72.75 in the last trading session. The last trading range of the stock ranges between $72.73 and $73.50. The company’s Market capitalization is $95.60 Billion with the total Outstanding Shares of 1.31 billion. Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The companys products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, in addition to diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners.
Southwest Airlines Co (NYSE:LUV), LOST -0.15% and closed at $41.32 in the last trading session. The last trading range of the stock ranges between $41.11 and $42.41. The company’s Market capitalization is $25.59 Billion with the total Outstanding Shares of 638.69 Million. During the 52-week trading session the minimum price at which share price traded, registered at $33.96 and reached to max level of $51.34. Southwest Airlines Co. (LUV) recently declared its flight plan of new nonstop service between Florida and Cuba, bringing Southwest’s legendary low fares to a ninth country and a historic 100th destination. Service between Fort Lauderdale-Hollywood International Airport (FLL) and Varadero, Cuba (VRA) is planned to begin Sunday, Nov. 13, 2016, and Havana (HAV) service is planned to begin Monday, Dec. 12, 2016, from both FLL and Tampa International Airport (TPA), subject to requisite approvals of the Cuban government. Service details for Santa Clara, Cuba (SNU) are intended to be released in the coming weeks.
“Southwest Customers can book their tickets now to travel to Cuba with our low fares and no hidden fees, bags fly free^, and the best Employees in the industry,” said Gary Kelly, Southwest Airlines’ Chairman, President & CEO. “Cuba will be the ninth country on our route map and Havana will mark Southwest’s 100th city, a noteworthyand proud milestone.”